-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TextPharmaceutical Guanlan
On January 20, Fosun Pharma announced that two new drugs under development of its holding subsidiary have started Phase 3 clinical trials in China
CDK4/6 inhibitor: FCN-437c
CDK4/6 inhibitor: FCN-437cFCN-437c is an innovative, orally active, second-generation selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) for development in the treatment of advanced/metastatic solid tumors (including HR+, HER2- advanced breast cancer)
According to the public information of Fosun Pharma, FCN-437c was conducted preclinical research by Fosun Pharma’s holding subsidiary, Fosun Pharma, and exclusively licensed to Aohong Pharma for development and commercialization in China
According to public information, FCN-437c has registered two phase 3 clinical trials of different combination therapies in China for patients with HR+ and HER2- advanced breast cancer; in the United States, FCN-437c monotherapy has a phase 1 clinical trial for advanced solid tumors.
ALK/ROS1 inhibitor: feritinib succinate capsules
ALK/ROS1 inhibitor: feritinib succinate capsulesForeritinib succinate (original project code name SAF-189) is an orally active small molecule inhibitor developed by Fuchuang Medicine, which can efficiently and targetedly inhibit anaplastic lymphoma kinase (ALK) and pro-ROS.
Public information shows that in early studies, feritinib succinate showed strong efficacy against ALK/ROS1 resistance mutations, had good anti-tumor effects, and was highly targeted to brain, lung and tumors tissue, with good pharmacokinetic profile and safety
According to the China Drug Clinical Trial Registration and Information Publicity Platform, a multi-center, open-label, randomized controlled phase 3 clinical study of feritinib succinate is currently underway to compare the candidate drug and the control drug in the treatment of ALK-positive late stage patients.
References:
[1] Announcement of Fosun Pharma on the progress of clinical trials of its controlled subsidiaries.
[2] Announcement of Fosun Pharma on the progress of drug clinical trials of its controlled subsidiaries.
[3] Fuchuang Medicine's new anti-tumor drug CDK4/6 inhibitor, the first patient in the US Phase I clinical trial.
[4] Official website of Fuchuang Medicine
